PR Newswire Clinical TrialsOriginal article
Mahzi Therapeutics Announces FDA Rare Pediatric Disease Designation for MZ-1866 Investigational Therapy for Pitt Hopkins Syndrome
RegulatoryMZ-1866Positive
AI Analysis
Summary
Mahzi Therapeutics announced FDA Rare Pediatric Disease Designation for MZ-1866, an investigational therapy for Pitt Hopkins Syndrome. The Phase 1/2 UNITE study is now more than 50% enrolled.
Clinical Trial Data
Phase
Phase 1/2
Outcome Details
FDA Rare Pediatric Disease Designation granted
Importance:6/10
Sentiment:
0.70
rare_diseaseneurogenetic_disorderpediatricregulatory_designationclinical_trial_enrollment
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 25, 2026 2:00 PM